Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li Y, Dobrolecki LE, Sallas C, Zhang X, Kerr TD, Bisht D, Wang Y, Awasthi S, Kaundal B, Wu S, Peng W, Mendillo ML, Lu Y, Jeter CR, Peng G, Liu J, Westin SN, Sood AK, Lewis MT, Das J, Yi SS, Bedford MT, McGrail DJ, Sahni N. Li Y, et al. Among authors: westin sn. Cell Rep Med. 2023 Dec 19;4(12):101326. doi: 10.1016/j.xcrm.2023.101326. Cell Rep Med. 2023. PMID: 38118413 Free PMC article.
The rise of genomic profiling in ovarian cancer.
Previs RA, Sood AK, Mills GB, Westin SN. Previs RA, et al. Among authors: westin sn. Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351. doi: 10.1080/14737159.2016.1259069. Expert Rev Mol Diagn. 2016. PMID: 27828713 Free PMC article. Review.
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Matulonis UA, et al. Among authors: westin sn. Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672. Ann Oncol. 2017. PMID: 27993796 Free PMC article. Clinical Trial.
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB. Sun C, et al. Among authors: westin sn. Sci Transl Med. 2017 May 31;9(392):eaal5148. doi: 10.1126/scitranslmed.aal5148. Sci Transl Med. 2017. PMID: 28566428 Free PMC article.
217 results